Y-39983

Y-39983

SCHEMBL29893202

CC(N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ROCK1ROCK2

The experimentally established mechanism targets of Y-39983. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 known ✓ O75116 7/20 1.00
ROCK1 known ✓ Q13464 5/20 1.00
CIT O14578 9/20 1.00
PRKD3 O94806 2/20 1.00
PRKACA P17612 2/20 1.00
PRKCQ Q04759 2/20 1.00
PRKCD Q05655 2/20 1.00
PKN2 Q16513 2/20 1.00
PRKD2 Q9BZL6 2/20 1.00
MAP4K4 O95819 1/20 1.00
PRKCB P05771 1/20 1.00
PRKCA P17252 1/20 1.00
CSNK2A2 P19784 1/20 1.00
MARK3 P27448 1/20 1.00
BMPR1A P36894 1/20 1.00
CSNK1A1 P48729 1/20 1.00
CLK1 P49759 1/20 1.00
GSK3A P49840 1/20 1.00
GSK3B P49841 1/20 1.00
CDK9 P50750 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Y-39983 SCHEMBL29431274 1.00 CIT (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL226556 1.00 CIT (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL25685649 1.00 CIT (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL226557 1.00 CIT (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL29816387 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL599801 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL599800 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL29666940 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL1927760 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA
Y-39983 SCHEMBL1927761 0.99 ROCK2 (1.00) CITROCK2ROCK1PRKD3PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014139-A1 Femtosecond Laser Treatment Methods PEYMAN GHOLAM A (US) 2026-01-15 US disclosed
US-11648261-B2 Method of treating, reducing, or alleviating a medical condition in a patient PEYMAN GHOLAM A (US) 2023-05-16 US disclosed
WO-2022211054-A1 METHOD FOR PRODUCING OVARIAN SOMATIC CELL-LIKE CELLS, AND METHOD FOR INDUCING DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS INTO OVARIAN SOMATIC CELL-LIKE CELLS 国立大学法人京都大学 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014139-A1 Femtosecond Laser Treatment Methods GSK3B, GSK3A, CTNND1 ROCK2 17/4885ROCK1 13/4885CIT 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.